MEMORANDUM


TOX CHEM No.: 527
TOX PROJECT No.: 7-0591
Record No.: 193465

FROM: John Doherty
Toxicology Branch
Hazard Evaluation Division (TS-769)

TO: George LaRocca
Product Manager #15
Registration Division (TS-767)

THRU: Edwin Budd
Section Head
Toxicology Branch
Hazard Evaluation Division (TS-769)

THRU: Theodore Farber, Ph.D.
Branch Chief
Toxicology Branch
Hazard Evaluation Division (TS-769)

Mr. Charles A. O'Connor counsel for Centre International d'Etudes du Lindane (CIEL) has submitted a revised final protocol for the rat chronic feeding/oncogenicity study with lindane. Toxicology Branch (TB) has previously reviewed protocols for this study (refer to J. Doherty memo dated December 24, 1986 and February 24, 1987 as well as earlier memos).
The CIEL and the Life Science Research Institute may proceed with the study as proposed in the February 1987 version of the protocol (LSR Schedule No. CIL/001/LIN). TB has no further comments or suggestions for the protocol.

TB requests, however, that information on the usage of both the Clinitest and N-Multistix to assess for urinary parameters be provided to the Agency as soon as possible. The information provided should include the limits of differences in concentration of the several urinary constituents which can be distinguished by these methods.

The registrants are reminded that it is their responsibility to provide a study that will satisfy the normal requirements for a chronic feeding/oncogenicity study as well as provide appropriate NOELs for the particular lesions in question for lindane toxicity (i.e. possible kidney and blood and bone marrow effects).
Page _____ is not included in this copy.
Pages 3 through 27 are not included.

The material not included contains the following type of information:

___ Identity of product inert ingredients.
___ Identity of product impurities.
___ Description of the product manufacturing process.
___ Description of quality control procedures.
___ Identity of the source of product ingredients.
___ Sales or other commercial/financial information.
___ A draft product label.
___ The product confidential statement of formula.
___ Information about a pending registration action.
√ FIFRA registration data.
___ The document is a duplicate of page(s) ________.
___ The document is not responsive to the request.

The information not included is generally considered confidential by product registrants. If you have any questions, please contact the individual who prepared the response to your request.